Tonix Pharmaceuticals Holding Corp. 8-K

What Happened
Tonix Pharmaceuticals (TNXP) filed an 8‑K on Feb 3, 2026 disclosing preliminary, unaudited operating results for the quarter and year ended December 31, 2025, and certain financial condition data as of January 30, 2026. The company reported approximately $207.6 million in cash and cash equivalents at year‑end, a preliminary net loss of about $118.9 million for 2025, and net product revenue of approximately $13.1 million. Tonix says these preliminary figures are subject to change and expects to file its Form 10‑K around March 16, 2026.

Key Details

• Cash & shares: $207.6M cash and cash equivalents at Dec 31, 2025; 12,793,952 common shares outstanding as of Jan 30, 2026.
• Revenue: Total net product revenue ~$13.1M for 2025 — Zembrace® SymTouch® and Tosymra® ~$11.7M; TONMYA™ ~$1.4M (sales from Nov 17–Dec 31, 2025).
• Operating cash and capex: Net cash used in operations ~$99.0M in 2025 (vs $60.9M in 2024); capital expenditures ~$3.4M in 2025 (vs $0.1M in 2024).
• Other: Company believes cash resources at Dec 31, 2025 should fund planned operations and capital needs into Q1 2027. Preliminary results are unaudited and EisnerAmper LLP has not audited or reviewed these numbers.

Why It Matters
These preliminary results give investors an early look at Tonix’s 2025 performance: revenue from marketed products increased from 2024, the net loss narrowed slightly year‑over‑year, but operating cash burn rose. The stated cash balance and management’s runway estimate are key for assessing near‑term funding needs; however, the numbers are preliminary and unaudited, so final 10‑K figures (expected ~Mar 16, 2026) may differ. Investors should treat this information with caution until audited financial statements are filed.